Tamoxifen, which interferes with estrogen for receptor binding, was the fi rst successful targeted therapy and has been the treatment of choice for estrogen receptor (ER)-positive breast cancers for more than two decades. Unfortunately, resistance occurs in approximately 30% of patients and the mechanisms of resistance act directly on the ER pathway and/or activate parallel pathways that block the anti-proliferative and pro-apoptotic actions of tamoxifen [1, 2] . For example, increased mitogenactivated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling downstream of growth factor receptors (for example, ERBB2 and Insulin-like growth factor 1 receptor (IGF-1R)) has been implicated in a crosstalk with ER and in resistance to endocrine therapy [1] [2] [3] .
Background
Tamoxifen, which interferes with estrogen for receptor binding, was the fi rst successful targeted therapy and has been the treatment of choice for estrogen receptor (ER)-positive breast cancers for more than two decades. Unfortunately, resistance occurs in approximately 30% of patients and the mechanisms of resistance act directly on the ER pathway and/or activate parallel pathways that block the anti-proliferative and pro-apoptotic actions of tamoxifen [1, 2] . For example, increased mitogenactivated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling downstream of growth factor receptors (for example, ERBB2 and Insulin-like growth factor 1 receptor (IGF-1R)) has been implicated in a crosstalk with ER and in resistance to endocrine therapy [1] [2] [3] .
Th e PI3K pathway, a central regulator of diverse normal cellular functions, is very often subverted during neoplastic transformation and contributes to several hallmarks of cancer that result in a competitive advantage for cancer cells [4] [5] [6] . Not surprisingly, the PI3K cascade is an attractive therapeutic target and several inhibitors are currently in phase I/II clinical trials. Preclinical studies have shown that PI3K inhibition circumvents resistance to trastuzumab in ERBB2-positive breast cancers and this has led to clinical trials combining anti-ERBB2 and anti-PI3K therapies [7] . Although PI3K has been implicated in resistance to endocrine therapy of ERpositive tumors, several questions remain unanswered. Is PI3K inhibition, alone or in combination with tamoxifen, eff ective in tamoxifen-resistant ER-positive cancer cells? Does PI3K inhibition block the emergence of tamoxifen resistance? Does a PI3K hyperactivation signature in human tumors predict tamoxifen sensitivity? Two recent papers now provide some answers to these outstanding questions.
The articles
Creighton and colleagues [8] investigated the relationship between the PI3K pathway and ER levels and activity using breast cancer cell lines and data sets of human breast tumors, and they defi ned proteomic and transcriptomic signatures of a hyperactivated PI3K pathway. Th ese signatures negatively correlate with ER levels within ER-positive human breast tumors and are associated with the luminal B breast cancer subtype, the more aggressive subtype of ER-positive tumors. In addition, the transcriptomic signature was shown to predict the worst prognosis in ER-positive tumors. Treatment with the dual PI3K/mammalian target of rapamycin (mTOR) inhibitor BEZ235 increased ER expression in a number of ER-positive breast cancer cell lines. Interestingly, treatment of two luminal B ER-positive cell lines simultaneously with tamoxifen and BEZ-235 reduced cell proliferation more than with either inhibitor alone. Of note, luminal A tumors might also benefi t from PI3K inhibition as the luminal A cell lines used by Creighton and colleagues [8] and by Miller and colleagues [9] are also sensitive to BEZ235.
Whether hyperactivation of the PI3K pathway contributes to tamoxifen resistance after chronic tamoxifen treatment was not addressed by this study, but was Abstract Seventy percent of breast tumors are estrogen receptor (ER) positive. Although endocrine therapy is successful for the majority of patients with ER-positive tumors, approximately 30% show de novo or acquired resistance and the underlying molecular mechanisms and biomarkers that predict such resistance remain elusive. Two recent papers report that hyperactivation of the phosphatidylinositol 3-kinase (PI3K) pathway produces resistance to tamoxifen. This raises the possibility that combining endocrine therapy and PI3K inhibition may be more eff ective than monotherapy for treating ER-positive breast tumors, either as fi rst-line therapy for tumors with high PI3K activity or after the development of resistance to endocrine therapy. answered by Miller and colleagues [9] , who generated estrogen-independent breast cancer cell lines from estrogen-dependent ER-positive lines by long-term estrogen deprivation (LTED). Unbiased phosphoprotein microarrays, immunocapture arrays and transcription profi ling revealed an increase in PI3K/mTOR signaling as a consequence of higher phosphorylation of the insulin receptor and/or IGF-1R in LTED cells compared with parental cells. Inhibition of PI3K/mTOR using BEZ235 [10] reduced cell growth in both parental and LTED cells and increased apoptosis in most of them. It remains unclear whether LTED cells are more reliant on the PI3K pathway for survival than their parental counterparts as BEZ235 caused a similar level of apoptosis in the two lines. Finally, the authors found that the protein signature of activated PI3K signaling predicted disease outcome after adjuvant endocrine therapy [9] .
The viewpoint
Both studies highlight the role of the PI3K pathway in resistance to tamoxifen. Creighton and colleagues [8] suggest that this eff ect is caused by PI3K-mediated downregulation of ER. Th is is also supported by the observation of Miller and colleagues [9] that PI3K pathway activation is inversely correlated with expression of ER in 64 human ER-positive breast tumors. As two lines (MCF7-LTED, HCC1428-LTED) used by Miller and colleagues showed a hyperactivated PI3K pathway compared with parental cells, but no decrease in ER expression, it is conceivable that further mechanisms account for PI3K-mediated resistance [9] . Altogether, the two studies suggest that targeting PI3K/mTOR and ER should be eff ective in ER-positive tumors and warrant complementary studies using in vivo models. Indeed, the interaction of cancer cells with the stroma might modulate estrogen sensitivity and lead to diff erent mechanisms of resistance [2] .
Although these studies might suggest that ER-positive tumors with a hyperactivated PI3K pathway should correlate with poor prognosis, this does not seem to be the case, at least for tumors showing activation of the PI3K pathway driven by PIK3CA mutations. Indeed, three recent studies reported that mutations of PIK3CA, in particular the catalytic domain mutation H1047R, are associated with better prognosis in ER-positive breast cancers [11] [12] [13] . Th is is surprising given the transforming eff ect of PIK3CA mutations in experimental systems. One possible explanation for this 'PIK3CA paradox' is that most experimental models assess eff ects on primary tumor growth and not metastases and long-term survival. Alternatively, PIK3CA mutations might only moderately activate the pathway and/or constitutive activity of mutant PIK3CA may induce negative feedback loops that preclude a more pronounced activation of the pathway [14] . In fact, several cell lines with PIK3CA muta tions (MCF-7, BT-483, MB-361) [15] were associated with a low/intermediate PI3K score in the proteomic signature of Creighton and colleagues [8] . Th erefore, better experimental models and systems biology-like assessment of the PI3K network, including the activities of all intermediates of the pathway, associated feedback loops and collaborating oncogenic pathways, may be needed to solve the 'PIK3CA paradox' . In summary, these two studies suggest hyperactivation of PI3K as a mechanism of resistance to tamoxifen, which may have clinical impact. It is reasonable to conclude that the combination of endocrine therapy and inhibition of PI3K in ER-positive tumors with a hyperactive PI3K pathway may be more eff ective than monotherapy. Studies on in vivo breast cancer models with alterations in the PI3K pathway should increase our understanding of this complex but fascinating signaling network, test the validity of this speculation and optimize combination therapies. Ultimately, clinical trials testing combinations of anti-ER and anti-PI3K therapies may fi nally lead to relapse-free therapy for patients with ER-positive tumors.
